Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma (SPL) has reported that AstraZeneca will expand the clinical program for a drug candidate which uses its proprietary drug delivery technology
- The trial of AZD0466 will be rolled out as a multi-centre global Phase 1 study and enrol patients with acute leukaemias
- Starpharma’s dendrimer-based drug delivery platform, or DEP technology, has been shown to improve efficiencies, reduce toxicities and be able to target particular areas of the body
- The global biopharmaceutical company has applied the tech to its own pipeline and used it in partnership with pharmaceutical companies such as AstraZeneca
- SPL shares have been trading 6.7 per cent higher at $2.08
Starpharma (SPL) has reported that AstraZeneca will expand the clinical program for a drug candidate which uses its proprietary drug delivery technology.
The trial of AZD0466 will be rolled out as a multi-centre global Phase 1 study and enrol patients with acute leukaemias.
AstraZeneca’s AZD0466 is a nanomedicine formulation of its novel dual Bcl2/xL inhibitor which has demonstrated anti-cancer activity on haematological cancers in pre-clinical models.
Starpharma’s dendrimer-based drug delivery platform, or DEP technology, has been shown to improve efficiencies, increase soluability, extend the duration of drug activity and reduce toxicities.
In addition, it can also be used to help target drugs to particular organs, tissues or receptors in the body.
The global biopharmaceutical company has applied the tech internally and used it in partnership with pharmaceutical companies such as AstraZeneca.
“We are excited to see the global expansion of the clinical program for AZD0466 and AstraZeneca’s commitment to bringing this important medicine to patients in need, as quickly as possible,” said Starpharma CEO Dr Jackie Fairley.
“There has been great enthusiasm for the global study from investigators and we understand that the intention is to expedite development of AZD0466 with the objective of obtaining regulatory approval for specific indications of high unmet clinical need.”
SPL shares have been trading 6.7 per cent higher at $2.08 at 10:39 am AEDT.
